Up 16%: Opportunity Knocks for GW
Shares of GW Pharma were up 16% on potentially exciting news regarding its drug Epidiolex for patients suffering from treatment-resistant epilepsy. The study in question had 27 patients, 15% of whom were seizure-free after 12 weeks of treatment. There was also an impressive 44% mean overall reduction in seizure frequency.
Nonetheless, it's important for investors to remember that this was a tiny, non-placebo controlled trial, so it's hard to draw too many conclusions yet.
In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson talk about Epidiolex and GW's opportunities moving forward.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article Up 16%: Opportunity Knocks for GW originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.